Bexion Pharmaceuticals and the drugmaker’s investigational cancer treatment BXQ-350 is receiving lots of mainstream media coverage as a potential game changer.
As millions of people pay for home tests to check on ancestry or health risks, genetic data is becoming an increasingly valuable resource for drugmakers, triggering a race to create a DNA marketplace.
New SCOUT Poll Finds Americans Much Less Concerned About Security of Personal Health Information than Threats to Financial Information
Americans may have a false sense of security about the privacy and safety of their personal medical information.
Google’s Verily will team up with ResMed, a company that specializes in treating sleep disorders, to launch a joint business venture to address sleep apnea and other sleeping disorders.
AstraZeneca suffered the company’s biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Yet now two-thirds of analysts tracked by Thomson Reuters recommend the stock, making it one of the sector’s biggest consensus buys, and CEO Pascal Soriot says he is “absolutely” happy to carry on into the 2020s as he chases early use of modern cancer drugs.
BBK Worldwide – for 35 years on the crest of the wave with regard to the development and evolution of the patient recruitment industry – announced its new marketplace position as The Patient Experience Company.
A clinical trial showed positive survival data for Swiss drugmaker Roche’s potential immunotherapy cocktail as an initial treatment for an aggressive form of lung cancer.
Novartis Receives FDA Approval For New Prescribing Information For Blockbuster PsA Treatment Cosentyx
FDA approved inclusion of new evidence that Cosentyx significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).
Roche is paying $2.4 billion to buy the rest of Foundation Medicine, raising the Swiss drugmaker’s bet on the U.S. genomic profiling group’s ability to personalize cancer care.
Watertown, Mass.-based Selecta Biosciences is eying a Phase III trial for its gout treatment based on expanded positive data from an ongoing mid-stage study that showed a significant reduction of serum uric acid at 12 weeks.
Innoplexus CEO Gunjan Bhardwaj responded to questions from Med Ad News about his company’s study of consumer perceptions of the pharma industry.
The irony of marketing in 2018 is that while our opportunities to engage with customers continuously expand through a myriad of new, increasingly digital, channels, human brains remain stubbornly analog.
Madrigal Pharmaceuticals’ shares more than doubled after mid-stage trial data showed the company’s lead drug reduced liver fat in patients with fatty liver disease.
China has overtaken the United States in healthy life expectancy at birth for the first time, according to World Health Organization data.
Novartis’ foray into digital technology intensified as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies.
Roche and its subsidiaries are ramping up treatment options for multiple sclerosis. In April, the company acquired a regenerative therapy program for MS from Inception Sciences. Now, Roche’s Genentech announced new data showcasing the efficacy of Ocrevus in relapsing multiple sclerosis (RMS).
U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.
U.S. FDA staff flagged concerns about potentially fatal blood clots from higher doses of a rheumatoid arthritis drug developed by Eli Lilly and Co. and Incyte Corp.
The U.S. FDA accepted Alkermes’ New Drug Application (NDA) for ALKS 5461, a treatment for major depressive disorder
Blockchain is best known as being linked to the cryptocurrency Bitcoin. For those a bit more in the know, it is the underlying data infrastructure that allows Bitcoin to work.